Special Edition 2021

First page Table of contents Next page Last page

Editorial: Doing one’s job	4
NEW PRODUCTS	2
Ebola vaccine rVSV-Zebov(ervebo°) in an outbreak of Ebola virus disease: Major reduction in incidence among those at risk for this often-fatal infection	5
Fexinidazole (fexinidazole winthroP°) and sleeping sickness caused by Trypanosoma brucei gambiense Effective and more convenient than injectable treatments	6
Polatuzumab vedotin (Polivy°) and large B-cell lymphoma	7
Remdesivir (veklury°) and covid-19: Too many uncertainties over its efficacy as well as its harms	8
Authorisation of remdesivir in the European Union: EMA needs to prioritise patients’ interests	9
Dasatinib in children (sPrycel° and other brands) with acute lymphoblastic leukaemia	10
Failure to demand solid evidence for marketing authorisation spells danger for patients	11
ADVERSE EFFECTS	12
VEGF inhibitors : arterial aneurysm and dissection	12
Apixaban, edoxaban, rivaroxaban: situations with a high risk of bleeding or thrombosis	13
Liposomal forms of drugs: now specified in the brand name, but no improvement to the INN	14
REVIEWS	15
Medical cannabis in chronic pain An option for some types of pain, while awaiting further evaluation	15
Hydrochlorothiazide in hypertension: An acceptable first choice	16
OUTLOOK	17
Towards better patient care: drugs to avoid in 2021	17
Drugs in 2020: a brief review	20
Drug shortages : a (big) thorn in the side of pharmacists	21
Towards transparency in the research costs of new drugs	22

Made with FlippingBook - professional solution for displaying marketing and sales documents online